Unlimited access to the most powerful analytical tools in finance.

23,8 % Ø-Performance der Fair-Value-Strategie seit 2003
Subscribe for $2
Overview
Profile
Aquestive Therapeutics Stock

Aquestive Therapeutics Stock - AQST

AQST
US03843E1047
A2JQ4G

Price

2.40
Today +/-
-0.10
Today %
-4.62 %

Aquestive Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aquestive Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aquestive Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aquestive Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aquestive Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aquestive Therapeutics Stock Price History

DateAquestive Therapeutics Price
5/20/20252.40 undefined
5/19/20252.51 undefined
5/16/20252.40 undefined
5/16/20252.34 undefined
5/15/20252.39 undefined
5/14/20252.24 undefined
5/13/20252.41 undefined
5/12/20252.61 undefined
5/9/20252.76 undefined
5/8/20252.68 undefined
5/7/20252.73 undefined
5/6/20252.69 undefined
5/5/20252.86 undefined
5/2/20253.06 undefined
5/1/20253.06 undefined
4/30/20252.96 undefined
4/29/20252.86 undefined
4/28/20252.88 undefined
4/25/20252.91 undefined
4/25/20252.94 undefined
4/24/20252.91 undefined
4/23/20252.88 undefined
4/22/20252.77 undefined
4/21/20252.55 undefined

Aquestive Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aquestive Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aquestive Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aquestive Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aquestive Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aquestive Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aquestive Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aquestive Therapeutics’s growth potential.

Aquestive Therapeutics Revenue, EBIT and net profit per share

DateAquestive Therapeutics RevenueAquestive Therapeutics EBITAquestive Therapeutics Net Income
2030e390.66 M undefined0 undefined0 undefined
2029e258.6 M undefined50.95 M undefined43.35 M undefined
2028e172.66 M undefined1.94 M undefined7.08 M undefined
2027e99.86 M undefined-36.98 M undefined-27.72 M undefined
2026e65.93 M undefined-52.85 M undefined-55.38 M undefined
2025e46.89 M undefined-52.24 M undefined-61.48 M undefined
202457.56 M undefined-30.77 M undefined-44.14 M undefined
202350.58 M undefined-15.1 M undefined-7.87 M undefined
202247.68 M undefined-42.07 M undefined-54.41 M undefined
202150.83 M undefined-34.68 M undefined-70.54 M undefined
202045.85 M undefined-42.89 M undefined-55.78 M undefined
201952.61 M undefined-52.66 M undefined-66.25 M undefined
201867.43 M undefined-48.93 M undefined-61.38 M undefined
201766.92 M undefined-110,000 undefined-11.42 M undefined
201651.79 M undefined-850,000 undefined-11.94 M undefined
20062.72 M undefined-12.2 M undefined-12.75 M undefined
20052.12 M undefined-7.79 M undefined-8.28 M undefined
20042.05 M undefined-3.52 M undefined-3.56 M undefined
200380,000 undefined-1.22 M undefined-1.22 M undefined

Aquestive Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20032004200520062016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0222516667524550475057466599172258390
----2,450.0029.411.52-22.39-13.4611.11-6.006.3814.00-19.3041.3052.3173.7450.0051.16
-1,950.001,950.0050.0068.6371.2168.6661.5471.1170.0059.5758.0068.4284.7860.0039.3922.6715.1210.00
0001354746323235282939000000
-1-3-8-12-11-11-61-66-55-70-54-7-44-61-55-277430
-200.00166.6750.00-8.33-454.558.20-16.6727.27-22.86-87.04528.5738.64-9.84-50.91-125.93514.29-
15.0315.0315.0315.0324.524.520.7325.3633.6538.0848.7361.2686.73000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aquestive Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aquestive Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20052006201620172018201920202021202220232024
                     
1.3315.269.2117.3860.649.3331.8128.0227.2723.8771.55
0.20.7710.666.16.4513.136.9612.124.78.477.34
0101608030000000
0.670.462.894.015.442.862.464.045.786.776.04
0.10.170.420.591.6833.43.082.131.853.29
2.316.6723.3428.1674.268.3244.6347.2639.8840.9788.22
7.618.5615.1213.4612.219.7310.327.789.39.748.98
00000000000
00000076543
1.91.660.310.250.20.440.10.051.441.280
00000000000
0.50.30.631.240.2400.840.91.451.441.22
10.0110.5216.0614.9512.6510.1718.2614.7317.1916.4513.2
12.3127.1939.443.1186.8578.4962.8961.9957.0757.42101.42
                     
11.349.8650.0151.50.030.030.040.040.060.070.09
5.201.46071.43124.32137.73174.62192.6212.52302.97
-11.84-24.6-108.67-120.09-61.38-130.47-186.26-256.8-311.21-319.08-363.21
00000000000
00000000000
4.6625.26-57.2-68.5910.08-6.12-48.49-82.14-118.55-106.49-60.16
1.251.16.649.620.4412.277.098.319.958.9310.29
0.190.732.953.816.995.239.39.648.226.896.42
001.221.940.931.052.141.992.662.472.14
00000000000
0.280004.602.582.0318.70.020.03
1.721.8310.8115.3532.9618.5521.1121.9739.5318.3118.87
5.93078.2787.6142.660.3434.3351.5533.4527.5132.5
00000000000
00.097.518.751.225.7155.9570.61102.65118.09110.22
5.930.0985.7896.3643.8266.0590.28122.16136.1145.6142.72
7.651.9296.59111.7176.7884.6111.39144.13175.63163.91161.58
12.3127.1839.3943.1286.8678.4862.961.9957.0857.42101.42
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aquestive Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aquestive Therapeutics's financial health and stability.

Assets

Aquestive Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aquestive Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aquestive Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aquestive Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20042005200620162017201820192020202120222023
-3-8-12-9-8-61-66-55-70-54-7
00133323221
00000000000
000-678-11-4-132-5
0013367211743148
00055678664
00000000000
-3-6-9-85-12-60-45-32-9-6
-1-2-30-2-1000-20
-1-2-30-2-1000-20
0001,0000000000
00000000000
010965017250-2-22
50160068396301317
410265458492830113
000-10-10-6-3009
00000000000
0113-2843-11-17-30-3
-4.63-9.16-12.64-9.163.75-14.81-60.87-45.98-33.89-12.31-7.38
00000000000

Aquestive Therapeutics stock margins

The Aquestive Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aquestive Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aquestive Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aquestive Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aquestive Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aquestive Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aquestive Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aquestive Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aquestive Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aquestive Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aquestive Therapeutics Margin History

Aquestive Therapeutics Gross marginAquestive Therapeutics Profit marginAquestive Therapeutics EBIT marginAquestive Therapeutics Profit margin
2030e68.95 %0 %0 %
2029e68.95 %19.7 %16.76 %
2028e68.95 %1.12 %4.1 %
2027e68.95 %-37.03 %-27.76 %
2026e68.95 %-80.15 %-83.99 %
2025e68.95 %-111.42 %-131.13 %
202468.95 %-53.46 %-76.68 %
202358.82 %-29.86 %-15.56 %
202259.33 %-88.23 %-114.11 %
202170.51 %-68.23 %-138.78 %
202071.73 %-93.54 %-121.66 %
201961.3 %-100.1 %-125.93 %
201868.87 %-72.56 %-91.03 %
201770.38 %-0.16 %-17.07 %
201668.37 %-1.64 %-23.05 %
200640.07 %-448.53 %-468.75 %
200539.62 %-367.45 %-390.57 %
200432.2 %-171.71 %-173.66 %
200337.5 %-1,525 %-1,525 %

Aquestive Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Aquestive Therapeutics earnings per share therefore indicates how much revenue Aquestive Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aquestive Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aquestive Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aquestive Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aquestive Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aquestive Therapeutics Revenue, EBIT and net profit per share

DateAquestive Therapeutics Sales per ShareAquestive Therapeutics EBIT per shareAquestive Therapeutics Earnings per Share
2030e4.5 undefined0 undefined0 undefined
2029e2.98 undefined0 undefined0.5 undefined
2028e1.99 undefined0 undefined0.08 undefined
2027e1.15 undefined0 undefined-0.32 undefined
2026e0.76 undefined0 undefined-0.64 undefined
2025e0.54 undefined0 undefined-0.71 undefined
20240.66 undefined-0.35 undefined-0.51 undefined
20230.83 undefined-0.25 undefined-0.13 undefined
20220.98 undefined-0.86 undefined-1.12 undefined
20211.33 undefined-0.91 undefined-1.85 undefined
20201.36 undefined-1.27 undefined-1.66 undefined
20192.07 undefined-2.08 undefined-2.61 undefined
20183.25 undefined-2.36 undefined-2.96 undefined
20172.73 undefined-0 undefined-0.47 undefined
20162.11 undefined-0.03 undefined-0.49 undefined
20060.18 undefined-0.81 undefined-0.85 undefined
20050.14 undefined-0.52 undefined-0.55 undefined
20040.14 undefined-0.23 undefined-0.24 undefined
20030.01 undefined-0.08 undefined-0.08 undefined

Aquestive Therapeutics business model

Aquestive Therapeutics Inc is a biopharmaceutical company based in Warren, New Jersey. The company specializes in the development of drugs for neurological disorders, rare diseases, and other medical needs. It was founded in 2004 and went public in 2018. The company operates in two main business segments: the development of proprietary drugs and the development of film technology for drug delivery. Both segments are closely connected and aim to provide innovative solutions for urgent medical needs. Aquestive's first business segment is the development of proprietary drugs for neurological disorders such as epilepsy, Parkinson's disease, and migraines. The company has various drug candidates in the pipeline, including a film-based sublingual tablet for the treatment of epilepsy and an injection solution for Parkinson's. These drug candidates are designed to complement or improve existing treatment options and achieve higher efficacy and tolerability for patients. Aquestive's second business segment is the development of film technology for drug delivery. Aquestive's patented film technology enables fast and reliable drug administration and can help improve the treatment of many diseases. Aquestive's film technology is particularly designed for drug administration through the mucous membranes of the mouth and throat. This includes film formulations for sublingual, buccal, or oromucosal drug delivery. An example of an Aquestive product is the sublingual film formulation of diazepam, marketed under the trade name Sympazan. Sympazan is approved for the treatment of LGS (Lennox-Gastaut syndrome), a rare and severe form of epilepsy. The sublingual film formulation of diazepam provides rapid onset of action and increased tolerability for patients compared to traditional dosage forms such as tablets or capsules. Aquestive has also specialized in the development of generic drugs for mucous membrane administration. The company produces sublingual, buccal, and oromucosal film formulations for a variety of medications, including drugs for pain, allergies, and nausea. Aquestive's generic drugs offer higher efficacy and tolerability for patients compared to conventional dosage forms such as tablets or capsules. Overall, Aquestive is an innovative company dedicated to improving patients' lives through novel therapeutic approaches. The company specializes in the development of film technology for drug delivery, providing a variety of innovative solutions for urgent medical needs. With its proprietary drug candidates and expertise in film technology, Aquestive is well-positioned to continue offering groundbreaking solutions for medical care. Aquestive Therapeutics is one of the most popular companies on Eulerpool.com.

Aquestive Therapeutics SWOT Analysis

Strengths

Aquestive Therapeutics Inc possesses several strengths that contribute to its success in the industry. Firstly, the company has a strong portfolio of innovative and proprietary pharmaceutical products, allowing it to cater to a wide range of therapeutic areas. This diverse product portfolio provides Aquestive Therapeutics Inc with a competitive edge in the market.

Furthermore, the company boasts a highly experienced and talented research and development team. Their expertise allows Aquestive Therapeutics Inc to continually develop and enhance its products, driving innovation and ensuring the company stays at the forefront of medical advancements.

Additionally, Aquestive Therapeutics Inc has established strategic partnerships and collaborations with key industry players. These partnerships grant the company access to additional resources, expertise, and distribution channels, enabling greater market reach and potential for growth.

Weaknesses

Aquestive Therapeutics Inc also faces certain weaknesses that may pose challenges to its operations and growth. One weakness is the company's heavy reliance on a limited number of products for its revenue generation. This dependency exposes Aquestive Therapeutics Inc to the risk of declining revenues if any of these key products face regulatory issues or market competition.

Additionally, the company is relatively small in size compared to some of its competitors. This may limit its resources and capabilities to effectively compete on a global scale, especially in terms of marketing, distribution, and research and development investments.

Opportunities

Aquestive Therapeutics Inc operates in an industry with several promising opportunities. One significant opportunity lies in the growing demand for effective therapies in various therapeutic areas. As the global population continues to face health challenges, there is an increasing need for innovative pharmaceutical products and treatment solutions, which Aquestive Therapeutics Inc can capitalize on.

Additionally, the company can explore expansion into international markets, leveraging its existing partnerships and collaborations to access new customers and gain a competitive advantage. This expansion can help diversify revenue streams and reduce reliance on a single market.

Threats

Aquestive Therapeutics Inc operates in an industry that is highly regulated and subject to intense competition. This poses a threat to the company's market position and profitability. Aquestive Therapeutics Inc needs to stay compliant with evolving regulations and stay ahead of the competition by continually investing in research and development and maintaining product superiority.

Another threat to the company is the potential for patent expirations or challenges from generic drug manufacturers. Aquestive Therapeutics Inc needs to actively protect its intellectual property rights and effectively manage patent expirations to preserve its market share and revenue streams.

Aquestive Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Aquestive Therapeutics Revenue by Segment

Segmente20232021202020192018
Manufacture and supply revenue43.81 M USD----
License and royalty revenue5.38 M USD----
The aggregate revenue generated from Co-development and research fees---4.04 M USD-
Co-development and research fees1.4 M USD----
Proprietary product sales, net-----

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Aquestive Therapeutics Revenue by Segment

Segmente20232021202020192018
Royalty-989,000 USD-1.1 M USD---

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Aquestive Therapeutics Revenue by Segment

Segmente20232021202020192018
The aggregate revenue generated from manufacture and supply--24.88 M USD38.74 M USD37.32 M USD
The aggregate revenue generated from licensing and royalties--14.06 M USD6.96 M USD24.7 M USD
Manufacture and supply revenue-35.31 M USD---
The aggregate revenue generated from proprietary product sales--5.65 M USD2.87 M USD228,000 USD
Proprietary product sales, net-8.51 M USD---
The aggregate revenue generated from Co-development and research fees--1.26 M USD-5.18 M USD
License and royalty revenue-5.38 M USD---
Co-development and research fees-1.64 M USD---

Aquestive Therapeutics Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Aquestive Therapeutics Revenue by Segment

DateEx-United StatesEx-United States revenues comprise the Australian and Malaysian marketsUnited States
202313.48 M USD-37.1 M USD
20217.97 M USD-42.86 M USD
20204.89 M USD-40.96 M USD
20194.32 M USD-48.29 M USD
2018-2.87 M USD64.57 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aquestive Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aquestive Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aquestive Therapeutics shares outstanding

The number of shares was Aquestive Therapeutics in 2024 — This indicates how many shares 86.726 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aquestive Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aquestive Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aquestive Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aquestive Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Aquestive Therapeutics.

Aquestive Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2025-0.17 -0.24  (-38.41 %)2025 Q1
12/31/2024-0.14 -0.19  (-37.28 %)2024 Q4
9/30/2024-0.13 -0.13  (-0.62 %)2024 Q3
6/30/2024-0.13 -0.03  (76.28 %)2024 Q2
3/31/2024-0.08 -0.17  (-102.38 %)2024 Q1
12/31/2023-0.08 -0.11  (-34.8 %)2023 Q4
9/30/2023-0.12 -0.03  (74.03 %)2023 Q3
6/30/2023-0.12 -0.1  (16.94 %)2023 Q2
3/31/2023-0.19 -0.12  (37.76 %)2023 Q1
12/31/2022-0.24 -0.23  (2.29 %)2022 Q4
1
2
3

Eulerpool ESG Scorecard© for the Aquestive Therapeutics stock

Eulerpool World ESG Rating (EESG©)

19/ 100

🌱 Environment

15

👫 Social

21

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aquestive Therapeutics shareholders

%
Name
Stocks
Change
Date
11.31257 % Crestline Investors, Inc.9,810,958012/31/2024
6.36587 % BlackRock Institutional Trust Company, N.A.5,520,881166,54412/31/2024
5.01204 % The Vanguard Group, Inc.4,346,75482,95812/31/2024
3.17090 % Armistice Capital LLC2,750,0002,750,0009/30/2024
3.03229 % VR Adviser, LLC2,629,786-2,925,76912/31/2024
2.46154 % Franklin Advisers, Inc.2,134,796-631,74612/31/2024
1.90784 % Geode Capital Management, L.L.C.1,654,596-12,91912/31/2024
1.85853 % MPM BioImpact LLC1,611,833-184,91712/31/2024
1.73407 % State Street Global Advisors (US)1,503,8917,15212/31/2024
1.59595 % Barber (Daniel)1,384,107742,9083/22/2024
1
2
3
4
5
...
10

Aquestive Therapeutics Executives and Management Board

Mr. Daniel Barber

(48)
Aquestive Therapeutics President, Chief Executive Officer, Director (since 2014)
Compensation 2.5 M

Ms. Lori Braender

(68)
Aquestive Therapeutics Chief Compliance Officer, Senior Vice President, General Counsel, Corporate Secretary
Compensation 1.19 M

Mr. A. Ernest Toth

(65)
Aquestive Therapeutics Chief Financial Officer
Compensation 1.12 M

Mr. A. Mark Schobel

(68)
Aquestive Therapeutics Chief Innovation and Technology Officer (since 2015)
Compensation 810,019

Dr. Gregory Brown

(71)
Aquestive Therapeutics Independent Chairman of the Board
Compensation 150,768
1
2
3
4

Aquestive Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Midatech Pharma Stock
Midatech Pharma
SupplierCustomer0,940,820,87
Haisco Pharm Group A Stock
Haisco Pharm Group A
SupplierCustomer0,61-0,550,720,750,500,49
KemPharm Stock
KemPharm
SupplierCustomer-0,31-0,020,780,860,610,56
IntelGenx Technologies Stock
IntelGenx Technologies
SupplierCustomer-0,43-0,160,220,830,79-0,28
Indivior Stock
Indivior
SupplierCustomer-0,530,42-0,52-0,66-0,45-0,66
Mitsubishi Chemical Hldgs Stock
Mitsubishi Chemical Hldgs
SupplierCustomer-0,54-0,270,230,550,67-0,51
1

Most common questions regarding Aquestive Therapeutics

What values and corporate philosophy does Aquestive Therapeutics represent?

Aquestive Therapeutics Inc represents values of innovation, patient-centeredness, and collaboration. The company strives to revolutionize the way patients receive and experience medical treatments by developing and delivering innovative pharmaceutical solutions. Aquestive's corporate philosophy revolves around putting patients first, aiming to improve their quality of life through effective and convenient treatment options. The company's dedication to research and development, along with its focus on building strategic partnerships, enables Aquestive to bring transformative therapies to patients in need. Aquestive Therapeutics Inc's commitment to innovation and patient-centric approach sets it apart in the pharmaceutical industry.

In which countries and regions is Aquestive Therapeutics primarily present?

Aquestive Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Aquestive Therapeutics achieved?

Some significant milestones that Aquestive Therapeutics Inc has achieved include obtaining FDA approval for their flagship product, Sublocade, a once-monthly injectable treatment for opioid use disorder. In addition, the company has successfully launched other innovative pharmaceutical products, such as Sympazan, an oral film formulation for the treatment of seizures associated with Lennox-Gastaut syndrome. Aquestive Therapeutics Inc has also made progress in developing a diverse pipeline of potential therapies, leveraging their proprietary PharmFilm® technology. Overall, Aquestive Therapeutics Inc has demonstrated a commitment to advancing drug delivery technologies and improving patient outcomes.

What is the history and background of the company Aquestive Therapeutics?

Aquestive Therapeutics Inc, a pharmaceutical company founded in 2004, is focused on developing innovative treatments to improve patients' lives. They specialize in developing and commercializing medicines through their proprietary PharmFilm® drug delivery technology. With a strong commitment to transformative therapies, Aquestive Therapeutics has made significant progress in various therapeutic areas, including central nervous system disorders, and oral mucositis. By leveraging their extensive expertise and cutting-edge technology, they aim to address unmet medical needs and enhance patient outcomes. The dedication and unwavering pursuit of excellence have positioned Aquestive Therapeutics as a leader in the pharmaceutical industry.

Who are the main competitors of Aquestive Therapeutics in the market?

The main competitors of Aquestive Therapeutics Inc in the market include other pharmaceutical companies that operate in the same therapeutic areas. Some notable competitors are Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, and Johnson & Johnson. These companies offer similar products and services, targeting similar patient populations and disease areas. Aquestive Therapeutics Inc focuses on developing innovative treatments and drug delivery solutions, aiming to stand out in the market with its unique approach and industry expertise. However, maintaining a competitive edge is essential in the highly dynamic pharmaceutical industry, where constant innovation and market adaptation play a crucial role.

In which industries is Aquestive Therapeutics primarily active?

Aquestive Therapeutics Inc is primarily active in the pharmaceutical industry, specifically focused on developing and commercializing innovative treatments for various medical conditions. They specialize in providing solutions for central nervous system (CNS) disorders and oral films. With their advanced drug delivery technology, Aquestive Therapeutics Inc aims to improve patient outcomes and enhance treatment options.

What is the business model of Aquestive Therapeutics?

Aquestive Therapeutics Inc operates as a specialty pharmaceutical company. Its business model is focused on developing and commercializing differentiated products to address unmet medical needs. The company utilizes its proprietary PharmFilm® technology to develop and manufacture pharmaceutical products, including CNS (central nervous system) and RLS (restless legs syndrome) therapies. Aquestive Therapeutics aims to improve patient outcomes and enhance treatment experiences through its innovative drug delivery platforms. By leveraging its expertise in formulation science and regulatory capabilities, the company strives to provide effective and convenient therapeutic options for patients across various medical conditions.

What is the P/E ratio of Aquestive Therapeutics 2025?

The Aquestive Therapeutics P/E ratio is -3.38.

What is the P/S ratio of Aquestive Therapeutics 2025?

The Aquestive Therapeutics P/S ratio is 4.43.

What is the Quality Investing of Aquestive Therapeutics?

The Quality Investing for Aquestive Therapeutics is 4/10.

What is the revenue of Aquestive Therapeutics 2025?

The expected Aquestive Therapeutics revenue is 46.89 M USD.

How high is the profit of Aquestive Therapeutics 2025?

The expected Aquestive Therapeutics profit is -61.48 M USD.

What is the business model of Aquestive Therapeutics

Aquestive Therapeutics Inc is a biopharmaceutical company based in New Jersey that specializes in the development and commercialization of innovative therapies for the treatment of various neurological disorders. Their business strategy is based on a wide range of products and services that provide greater benefits to customers and patients. Here is an overview of the company's business model and products. The business model: Aquestive Therapeutics Inc aims to revolutionize the innovative biopharmaceutical industry through their services and products. Their goal is to develop innovative solutions that help patients improve their quality of life and treat currently incurable diseases. The company has developed a unique platform technology that allows for the oral administration of medications that would normally only be administered through injections or infusions. The products: Aquestive Therapeutics Inc offers a wide range of innovative therapies for the treatment of neurological disorders such as Parkinson's disease, epilepsy, and akathisia. Their products are also intended for the treatment of central nervous system disorders such as stroke and multiple sclerosis. The products include: - Exservan: A chewable medication for the treatment of amyotrophic lateral sclerosis (ALS) and motor neuron disease. - Sympazan: For the treatment of Lennox-Gastaut syndrome, a severe form of epilepsy in children aged two and older. - Subsys: A highly effective fentanyl-containing sublingual spray formulation for the treatment of acute pain in patients who are opioid-dependent due to cancer. - Libervant: An oral spray for the treatment of acute recurring seizures in adults, as well as for the preventive protection against epileptic seizures. - AQST-117 (Riluzole): Developed for the treatment of amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases of the nervous system. - AQST-108: A transdermal medication for the treatment of uncontrolled movements caused by neuroleptics and antiemetics. Aquestive Therapeutics Inc also offers clinical trials to further research and improve their new technology and products. They have conducted extensive research and development activities to address rapidly evolving and dynamic markets for novel treatments. Additionally, the company has formed partnerships with other industry leaders to further accelerate growth. Conclusion: Aquestive Therapeutics Inc has proven that they can operate as one of the fastest-growing biopharmaceutical companies in the industry. With their innovative technology and product portfolio, they have redefined industry standards. Their extensive research and development capabilities give the company a competitive edge in the emerging biopharmaceutical industry. In the future, the company has the opportunity to expand its business through strategic partnerships and collaboration with other leading companies and institutions.

What is the Aquestive Therapeutics dividend?

Aquestive Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Aquestive Therapeutics pay dividends?

The dividend cannot currently be calculated for Aquestive Therapeutics or the company does not pay out a dividend.

What is the Aquestive Therapeutics ISIN?

The ISIN of Aquestive Therapeutics is US03843E1047.

What is the Aquestive Therapeutics WKN?

The WKN of Aquestive Therapeutics is A2JQ4G.

What is the Aquestive Therapeutics ticker?

The ticker of Aquestive Therapeutics is AQST.

How much dividend does Aquestive Therapeutics pay?

Over the past 12 months, Aquestive Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aquestive Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aquestive Therapeutics?

The current dividend yield of Aquestive Therapeutics is .

When does Aquestive Therapeutics pay dividends?

Aquestive Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aquestive Therapeutics?

Aquestive Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aquestive Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aquestive Therapeutics located?

Aquestive Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aquestive Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aquestive Therapeutics from 5/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/20/2025.

When did Aquestive Therapeutics pay the last dividend?

The last dividend was paid out on 5/20/2025.

What was the dividend of Aquestive Therapeutics in the year 2024?

In the year 2024, Aquestive Therapeutics distributed 0 USD as dividends.

In which currency does Aquestive Therapeutics pay out the dividend?

The dividends of Aquestive Therapeutics are distributed in USD.

All fundamentals about Aquestive Therapeutics

Our stock analysis for Aquestive Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aquestive Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.